InvestorsHub on MSN
Beam Therapeutics shares climb after positive BEAM-302 trial update
Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) gained about 8% on Wednesday after the company released updated results from ...
Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM ...
Beam Therapeutics Inc. (NASDAQ:BEAM) rose 8% Tuesday after announcing updated clinical data from its ongoing Phase 1/2 trial of BEAM-302 in alpha-1 antitrypsin deficiency (AATD). The company reported ...
BEAM-302 demonstrated safety and efficacy in increasing AAT levels and reducing mutant protein in alpha-1 antitrypsin deficiency patients. Beam Therapeutics announced promising initial results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results